Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Abstract 5735: Comprehensive analysis of serum levels of VEGF and its receptors in patients with uterine cervical cancer

Daiken Osaku, Tetsuro Oishi, Mayumi Sawada, Hiroaki Komatsu, Jun Chikumi, Akiko Kudoh, Michiko Nonaka, Shinya Sato, Muneaki Shimada, Hiroaki Itamochi, Tasuku Harada

Cancer Res (2017) 77 (13_Supplement): 5735.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5735

Published: 01 July 2017

View article

Journal Articles

Abstract 529: The significance of activated PI3K/AKT pathway in FGFR3-TACC3 fusion positive cervical cancer

Ryo Tamura, Kosuke Yoshihara, Tetsuya Saito, Ryosuke Ishimura, Emmanuel Martínez-Ledesma, Yutaro Mori, Kaoru Yamawaki, Kazuaki Suda, Tatsuya Ishiguro, Yoichi Aoki, Seiya Sato, Hiroaki Itamochi, Masaaki Komatsu, Roeland Verhaak, Takayuki Enomoto

Cancer Res (2017) 77 (13_Supplement): 529.

DOI: https://doi.org/10.1158/1538-7445.AM2017-529

Published: 01 July 2017

View article

Journal Articles

Abstract 3380: Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma

Katrien Berns, Joseph J. Caumanns, E Marielle Hijmans, Annemiek Gennissen, Bastiaan Evers, Bea A. Wisman, Gert Jan Meersema, Cor Lieftink, Roderick L. Beijersbergen, Hiroaki Itamochi, Ate G. van der Zee, Steven de Jong, René Bernards

Cancer Res (2017) 77 (13_Supplement): 3380.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3380

Published: 01 July 2017

View article

Journal Articles

Abstract 3387: Serum VEGF-A may predict prognosis in patients with epithelial ovarian cancer

Hiroaki Komatsu, Tetsuro Oishi, Hiroaki Itamochi, Mayumi Sawada, Michiko Nonaka, Seiya Sato, Jun Chikumi, Shinya Sato, Muneaki Shimada, Tasuku Harada

Cancer Res (2016) 76 (14_Supplement): 3387.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3387

Published: 15 July 2016

View article

Journal Articles

Abstract 643: Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1

Seiya Sato, Nao Oumi, Hiroaki Itamochi, Tetsuro Oishi, Tasuku Harada, Toru Sugiyama

Cancer Res (2016) 76 (14_Supplement): 643.

DOI: https://doi.org/10.1158/1538-7445.AM2016-643

Published: 15 July 2016

View article

Journal Articles

Abstract 3386: Serum VEGF-A may predict prognosis in patients with uterine cervical cancer

Mayumi Sawada, Tetsuro Oishi, Hiroaki Komatsu, Hiroaki Itamochi, Michiko Nonaka, Seitya Sato, Jun Chikumi, Sinya Sato, Sinya Sato, Muneaki Shimada, Tasuku Harada

Cancer Res (2016) 76 (14_Supplement): 3386.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3386

Published: 15 July 2016

View article

Journal Articles

Abstract 1102: Integrated genomic analysis of clear-cell ovarian cancer identifies PRKCI as a therapeutic target

Tsun Yee Tsang, Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok, Michael J. Birrer

Cancer Res (2015) 75 (15_Supplement): 1102.

DOI: https://doi.org/10.1158/1538-7445.AM2015-1102

Published: 01 August 2015

View article

Journal Articles

Abstract 5298: Serum angiogenic factors may predict prognosis in patients with epithelial ovarian cancer

HIROAKI KOMATSU, Tetsuro Oishi, Hiroaki Itamochi, Akiko Kudoh, Michiko Nonaka, Seiya Sato, Jun Chikumi, Shinya Sato, Muneaki Shimada, Junzo Kigawa, Tasuku Harada

Cancer Res (2015) 75 (15_Supplement): 5298.

DOI: https://doi.org/10.1158/1538-7445.AM2015-5298

Published: 01 August 2015

View article

Journal Articles

Abstract 3556: Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

Hiroaki Itamochi, Nao Oumi, Tetsuro Oishi, Fuminori Taniguchi, Tadahiro Shoji, Hiroyuki Fujiwara, Toru Sugiyama, Mitsuaki Suzuki, Junzo Kigawa, Tasuku Harada

Cancer Res (2015) 75 (15_Supplement): 3556.

DOI: https://doi.org/10.1158/1538-7445.AM2015-3556

Published: 01 August 2015

View article

Journal Articles

Abstract 1528: Identification of FGFR3 as a potential therapeutic target gene for human clear cell ovarian cancer by global genomic analysis

Tsun Yee Tsang, Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok, Michael J. Birrer

Cancer Res (2014) 74 (19_Supplement): 1528.

DOI: https://doi.org/10.1158/1538-7445.AM2014-1528

Published: 01 October 2014

View article

Journal Articles

Abstract 4742: Comprehensive analysis of the PI3K-Akt-mTOR pathway in epithelial ovarian carcinoma

Tetsuro Oishi, Hiroaki Itamochi, Nao Oumi, Misaki Kato, Tadahiro Shoji, Yasushi Saga, Hiroyuki Fujiwara, Muneaki Shimada, Toru Sugiyama, Mitsuaki Suzuki, Junzo Kigawa, Tasuku Harada

Cancer Res (2014) 74 (19_Supplement): 4742.

DOI: https://doi.org/10.1158/1538-7445.AM2014-4742

Published: 01 October 2014

View article

Journal Articles

Abstract 799: Global genomic analysis identified PRKCI as a potential therapeutic target gene for human clear cell ovarian cancer.

Tsun Yee Tsang, Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok, Michael J. Birrer

Cancer Res (2013) 73 (8_Supplement): 799.

DOI: https://doi.org/10.1158/1538-7445.AM2013-799

Published: 15 April 2013

View article

Journal Articles

Abstract 3256: A novel therapy for mucinous adenocarcinoma of the ovary by using NVP-BEZ235 to inhibit PI3K and mTOR.

Akiko Kudoh, Tetsuro Oishi, Hiroaki Itamochi, Michiko Nonaka, Seiya Sato, Jun Naniwa, Shinya Sato, Muneaki Shimada, Naoki Terakawa, Junzo Kigawa, Tasuku Harada

Cancer Res (2013) 73 (8_Supplement): 3256.

DOI: https://doi.org/10.1158/1538-7445.AM2013-3256

Published: 15 April 2013

View article

Journal Articles

Abstract 3740: NVP-BEZ235, a dual PI3K/ mTOR inhibitor, suppress tumorigenicity of ovarian clear cell carcinoma cells.

Tetsuro Oishi, Hiroaki Itamochi, Akiko Kudoh, Michiko Nonaka, Seiya Sato, Jun Naniwa, Shinya Sato, Muneaki Shimada, Naoki Terakawa, Junzo Kigawa, Tasuku Harada

Cancer Res (2012) 72 (8_Supplement): 3740.

DOI: https://doi.org/10.1158/1538-7445.AM2012-3740

Published: 15 April 2012

View article

Journal Articles

Abstract 4497: NVP-BEZ235, a dual PI3K/ mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells

Tetsuro Oishi, Hiroaki Itamochi, Michiko Nonaka, Seiya Sato, Jun Naniwa, Kazunori Uegaki, Shinya Sato, Muneaki Shimada, Naoki Terakawa, Junzo Kigawa, Tasuku Harada

Cancer Res (2011) 71 (8_Supplement): 4497.

DOI: https://doi.org/10.1158/1538-7445.AM2011-4497

Published: 15 April 2011

View article

Journal Articles

Abstract 2561: Inhibiting the mTOR pathway synergistically enhances etoposide-induced cytotoxicity by upregulating c-Jun in ovarian cancer cells

Hiroaki Itamochi, Michiko Nonaka, Seiya Sato, Kazunori Uegaki, Jun Naniwa, Shinya Sato, Muneaki Shimada, Oishi Tetsuro, Naoki Terakawa, Junzo Kigawa, Tasuku Harada

Cancer Res (2011) 71 (8_Supplement): 2561.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2561

Published: 15 April 2011

View article

Journal Articles

Abstract 1619: ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15

Tetsuro Oishi, Chandra Bartholomeusz, Anna Kazansky, Ugur Akar, Savitori Krishunamurthy, Francisco J. Esteva, Hiroaki Itamochi, Naoto T. Ueno

Cancer Res (2010) 70 (8_Supplement): 1619.

DOI: https://doi.org/10.1158/1538-7445.AM10-1619

Published: 15 April 2010

View article

Journal Articles

Abstract 3543: Activation of the ERK pathways overcome the cisplatin-resistance in ovarian carcinoma cells

Michiko Nonaka, Hiroaki Itamochi, Wakae Kawaguchi, Kazunori Uegaki, Jun Naniwa, Shinya Sato, Muneaki Shimada, Tetsuro Oishi, Naoki Terakawa, Junzo Kigawa, Tasuku Harada

Cancer Res (2010) 70 (8_Supplement): 3543.

DOI: https://doi.org/10.1158/1538-7445.AM10-3543

Published: 15 April 2010

View article

Journal Articles

Abstract #2956: Activation of the ERK pathway enhances sensitivity to CDDP in ovarian carcinoma cells

Nonaka Michiko, Hiroaki Itamochi, Wakae Kawaguchi, Seiya Sato, Kazunori Uegaki, Jun Naniwa, Shinya Sato, Muneaki Shimada, Tetsuro Oishi, Junzo Kigawa

Cancer Res (2009) 69 (9_Supplement): 2956.

Published: 01 May 2009

View article

Journal Articles

Abstract #4580: Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy

Seiya Sato, Hiroaki Itamochi, Michiko Nonaka, Kazunori Uegaki, Jun Naniwa, Shinya Sato, Muneaki Shimada, Tetsuro Oishi, Junzo kigawa, Naoki Terakawa

Cancer Res (2009) 69 (9_Supplement): 4580.

Published: 01 May 2009

View article

NARROW

Abstract 5735: Comprehensive analysis of serum levels of VEGF and its receptors in patients with uterine cervical cancer

Abstract 529: The significance of activated PI3K/AKT pathway in FGFR3-TACC3 fusion positive cervical cancer

Abstract 3380: Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma

Abstract 3387: Serum VEGF-A may predict prognosis in patients with epithelial ovarian cancer

Abstract 643: Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1

Abstract 3386: Serum VEGF-A may predict prognosis in patients with uterine cervical cancer

Abstract 1102: Integrated genomic analysis of clear-cell ovarian cancer identifies PRKCI as a therapeutic target

Abstract 5298: Serum angiogenic factors may predict prognosis in patients with epithelial ovarian cancer

Abstract 3556: Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

Abstract 1528: Identification of FGFR3 as a potential therapeutic target gene for human clear cell ovarian cancer by global genomic analysis

Abstract 4742: Comprehensive analysis of the PI3K-Akt-mTOR pathway in epithelial ovarian carcinoma

Abstract 799: Global genomic analysis identified PRKCI as a potential therapeutic target gene for human clear cell ovarian cancer.

Abstract 3256: A novel therapy for mucinous adenocarcinoma of the ovary by using NVP-BEZ235 to inhibit PI3K and mTOR.

Abstract 3740: NVP-BEZ235, a dual PI3K/ mTOR inhibitor, suppress tumorigenicity of ovarian clear cell carcinoma cells.

Abstract 4497: NVP-BEZ235, a dual PI3K/ mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells

Abstract 2561: Inhibiting the mTOR pathway synergistically enhances etoposide-induced cytotoxicity by upregulating c-Jun in ovarian cancer cells

Abstract 1619: ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15

Abstract 3543: Activation of the ERK pathways overcome the cisplatin-resistance in ovarian carcinoma cells

Abstract #2956: Activation of the ERK pathway enhances sensitivity to CDDP in ovarian carcinoma cells

Abstract #4580: Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only